ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2018

First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma.

S Turajlic et al.PubMed ↗Publisher ↗

No numbers read from the abstract.